

GROUNDBREAKING HAE TREATMENT

ANDEMBRY transforms HAE management by targeting the pathway at the top.

WORKS
FAST—FROM
WEEK 1

>99%*
MEDIAN
REDUCTION IN
HAE ATTACKS[†]

89%*
LS MEAN
REDUCTION IN
HAE ATTACKS[†]

THE ONLY ONCE-MONTHLY DOSING
FROM THE START FOR ALL PATIENTS

A median reduction of >99% was calculated because at least half of the ANDEMBRY-treated patients experienced a complete reduction in monthly HAE attack rates compared to placebo. Patients receiving ANDEMBRY in the clinical trial experienced an adjusted average of 89% (LS; least squares) reduction in monthly HAE attack rate compared to placebo.

* With all HAE medications, attacks can still occur. Patients should always have a rescue medication.

† At 6 months.



Discover how **ANDEMBRY** may help you,
and get the info you need to talk to your doctor.

IMPORTANT SAFETY INFORMATION

What is ANDEMBRY?


ANDEMBRY® (garadacimab-gxii) injection, for subcutaneous use, is a prescription medication used to prevent attacks of hereditary angioedema (HAE) in people 12 years and older.

It is not known if ANDEMBRY is safe and effective in children under 12 years of age.

What should I tell my healthcare provider before using ANDEMBRY?

Before using ANDEMBRY, tell your healthcare provider about any medical condition you may have, especially if you are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed. It is not known if ANDEMBRY can harm your unborn baby or if ANDEMBRY passes into breastmilk. Talk to your healthcare provider about the best way to feed your baby while using ANDEMBRY.

Tell your healthcare provider about all medications you take, including prescription medicines, over-the-counter treatments, vitamins, and herbal supplements.



ANDEMBRY is the first and only approved prophylaxis treatment for HAE patients proven to work differently from other options by inhibiting Factor XIIa at the top of the HAE cascade.

-99%*

Median attack reduction at 6 months compared to placebo.

89%*

LS mean attack reduction at 6 months compared to placebo.



Simple Administration – Subcutaneous self-injection delivered in ≤15 seconds via a convenient autoinjector.



No reports of injection-site pain.[†]



ANDEMBRY Connect offers personalized support from a dedicated case manager to provide ongoing, one-on-one support throughout your ANDEMBRY journey.

* With all HAE medications, attacks can still occur. Patients should always have a rescue medication.

† In the VANGUARD pivotal phase 3 trial. Patients in the pivotal study and open-label extension study experienced injection-site redness, itching, and bruising.

LS, least squares

IMPORTANT SAFETY INFORMATION (cont'd)

How should I use ANDEMBRY?

Use ANDEMBRY exactly as instructed by your healthcare provider. Detailed instructions for use can be found in the patient information section of the full prescribing information.

ANDEMBRY is given as an injection under your skin (subcutaneous) by you or a caregiver. Your healthcare provider should show you or your caregiver how to prepare and inject your dose of ANDEMBRY before you inject yourself for the first time. **Do not** try to inject ANDEMBRY unless you have been trained by your healthcare provider.

What are the possible side effects of ANDEMBRY?

The most common side effects of ANDEMBRY include:

- Redness, itchiness, and bruising (injection-site reactions)
- Stomach (abdominal) pain
- Runny or stuffy nose, sneezing, watery eyes (nasopharyngitis)

Please see full prescribing information for ANDEMBRY, including patient information and instructions for use.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call **1-800-FDA-1088**.

You can also report side effects to CSL Behring's Pharmacovigilance Department at **1-866-915-6958**.

ANDEMBRY is manufactured by CSL Behring GmbH and distributed by CSL Behring LLC.

ANDEMBRY® is a registered trademark of CSL Behring GmbH.

ANDEMBRY ConnectSM is a service mark of CSL Behring LLC.

©2025 CSL Behring LLC.

1020 First Avenue, PO Box 61501, King of Prussia, PA 19406-0901 USA

www.CSLBehring.com www.ANDEMBRY.com USA-AND-0236-NOV25

CSL Behring